Effect of MK0524A on Cholesterol Levels (0524A-048)

NCT00536510 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

646

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Hyperlipidemia

Interventions

DRUG: laropiprant/niacin (MK0524A)
DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC